Isatuximab-carfilzomib-dexamethasone immediately after failing of the quadruplet Daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-VRD): Striking response with no washout in a newly diagnosed multiple myeloma.
In: Clinical case reports, Jg. 12 (2024-01-23), Heft 1, S. e8449
Online
report
Zugriff:
Biochemical evolution of serum IgG-Kappa monoclonal component during the first line with VRD (x1), DARA-VRD (x4), and the second line with ISA-KD (x4).
Competing Interests: GFJJ: Honoraria from Janssen, Bristol Myers Squibb, GlaxoSmithKline, Sanofi, and Amgen. GRP and CChM: no relevant financial relationships to disclose.
(© 2024 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
Titel: |
Isatuximab-carfilzomib-dexamethasone immediately after failing of the quadruplet Daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-VRD): Striking response with no washout in a newly diagnosed multiple myeloma.
|
---|---|
Autor/in / Beteiligte Person: | Gil-Fernández, JJ ; García Ramírez, P ; Callejas Charavía, M |
Link: | |
Zeitschrift: | Clinical case reports, Jg. 12 (2024-01-23), Heft 1, S. e8449 |
Veröffentlichung: | Chichester, UK : John Wiley & Sons, 2024 |
Medientyp: | report |
ISSN: | 2050-0904 (print) |
DOI: | 10.1002/ccr3.8449 |
Sonstiges: |
|